Good things come in 3s: New publications arising from EU funded collaborations on biomarker research and discovery

We are pleased to have been involved in this trio of papers examining biomarkers and genetic modifiers in Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). These studies were based on collaborative work under the BIO-NMD project led led by Alessandra Ferlini and funded by the European Union’s Seventh Framework Program from 2010-2012. Biomarkers are characteristics that can be used to monitor disease progression, response to treatment, and prognosis, while genetic modifiers are genes that can affect the expression of other genes and influence the phenotype of a patient. The discovery of biomarkers and genetic modifiers allows for more personalized treatments and advice to patients. While the publication of these papers may have taken longer than the funding duration, this does demonstrate the ability of research projects to have long-term impact many years following the conclusion of a project.

Capitanio et al., 2020 Showed mechanosensing and metabolic dysfunction as central features of BMD and DMD, with DMD demonstrating further dysregulation in extracellular matrix composition.

Is available open access on the Journal of Cachexia, Sarcopenia and Muscle website.

Spitali et al., 2020 demonstrated that variants in TCTEX1D1 on chromosome 1 were associated with age of ambulation loss.

Is available open access on the European Journal of Human Genetics website.

Signorelli et al., 2019 revealed that serum levels of MDH2 correlated with disease stage and response to treatment with corticosteroids; furthermore, they were associated with the risk of wheelchair dependency and pulmonary function.

Is available open access on the Journal of Cachexia, Sarcopenia and Muscle website.


Read next...

Congratulations to the four funding award recipients!

Four Research Lab Members Receive Funding Awards

We are excited to share that four of our research team members have received competitive funding awards to support their projects. Academic awards for individual...
Welcome to the team - new members of the Lochmuller Lab

Meet the lab’s new clinical members

Our lab is growing! We are excited to introduce several new clinical research staff members who have joined the Lochmüller lab since our last update,...

$109 million to fund Brain-Heart Interconnectome project to study brain-heart disorders

The CHEO Research Institute and the Lochmüller research group are excited to participate in a new uOttawa-led initiative funded by the Canada First Research Excellence...

8.8 million euros for accelerated drug repurposing for rare neurological disorders

International SIMPATHIC Consortium receives grant from European Commission The Children’s Hospital of Eastern Ontario Research Institute (CHEO RI) has received funding from the New Frontiers...
The new clinical trials list provides searchable and filterable information on the current trials the research team are conducting.

Lochmuller Lab clinical research webpage update

It’s now easier than ever to stay up-to-date on the clinical research trials that our team is involved in We are excited to share an...
Periostin paper image

New publication: Periostin as a blood biomarker of muscle cell fibrosis, cardiomyopathy and disease severity in myotonic dystrophy type 1

Lochmüller Lab members published as authors in Journal of Neurology study Myotonic dystrophy is the most common adult-onset muscular dystrophy and affects cardiac and endocrine...